恶性肿瘤患者尿液中可溶性尿激酶受体和胱抑素C水平检测的临床价值  

Clinical Value of Detection of Soluble Urokinase Receptor and Cystatin C in Urine of Patients with Malignant Tumor

作　　者：孙继兴[1] 王一[1] 李会平[1] 

机构地区：[1]河北省唐山市人民医院检验科,063001

出　　处：《职业与健康》2011年第21期2510-2511,共2页Occupation and Health

基　　金：河北省唐山市科学与发展计划项目(项目编号:08130206d)

摘　　要：目的探讨恶性肿瘤患者尿液中可溶性尿激酶受体(suPAR)和胱抑素C(Cystatin C)水平及与治疗的关系。方法 suPAR采用ELISA法检测。Cystatin C应用颗粒增强散射免疫比浊法(PENIA)检测,使用德灵BNII特定蛋白分析仪;对照组为82例健康成人,病例组为93例恶性肿瘤患者,比较2组尿液中suPAR和Cystatin C的检测水平。结果恶性肿瘤患者尿液中suPAR和Cystatin C水平较对照组增高,差异有统学意义(P<0.01)。结论与健康对照成人比较恶性肿瘤患者尿液中suPAR和Cystatin C水平增高,且与恶性肿瘤患者手术有关。检测恶性肿瘤患者尿液中suPAR和Cystatin C水平有可能成为新的诊断和预后判断指标,对恶性肿瘤患者病情监测和疗效判断具有较高的临床价值。[Objective]To explore the relationship between treatment and the levels of soluble urokinase receptor（suPAR） and Cystatin C in urine of patients with malignant tumor. [Methods]The level of suPAR was measured by ELISA,level of Cystatin C was measured by particles enhance nephelometry immune assay（PENIA）,and Dade Behring BNII special protein analysor was applied.82 healthy adults were involved in the control group,and 93 patients with malignant tumor were involved in the case group.The levels of suPAR and Cystatin C in urine of two groups were compared. [Results]The levels of suPAR and Cystatin C in urine of patients with malignant tumor were significantly higher than those of the control group（P0.01）. [Conclusion]The levels of suPAR and Cystatin C in urine of patients with malignant tumor were increased significantly compared with those of healthy adults,and it was related to operation of malignant tumor.The detection of suPAR and Cystatin C in urine of patients with malignant tumor may become a new index of diagnosis and prognosis,which has the important clinical value in monitoring and effect judgment in patients with malignant tumor.

关 键 词：恶性肿瘤 可溶性尿激酶受体 胱抑素C 

分 类 号：R730.43[医药卫生—肿瘤]